Resultados de búsqueda para “Vce SY0-701 Exam 💫 Exam SY0-701 Lab Questions 🍅 SY0-701 Latest Exam Fee 🙆 Search for ➠ SY0-701 🠰 on ▛ www.pdfvce.com ▟ immediately to obtain a free download 🙀Authorized SY0-701 Test Dumps”
Solar-Recur: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Solar-Stage: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Curium U.S. invoice terms and conditions of sale
Nuclear medicine education
Welcome customers Thank you for visiting our Nuclear Medicine Education website. Through this website we strive to provide a robust variety of Continuing Education (CE) programs relevant to the Nuclear Medicine Technologist. All courses are structured in a self-paced learning format, conveniently accessible 24 hours a day, 7 days a week, and include course assessments […]
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
Detectnet™
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
Ioflupane I 123 Injection
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
Ultra-Technekow™ V4
Ultra-Technekow™ V4
Recursos
Ultratag™ RBC
NRG and Curium Sign Multi-Year Isotope Production Contract
Kit for the Preparation of Technetium Tc99m Sestamibi Injection
Technescan MAG3™
Ultratag™ RBC
Kit for the Preparation of Technetium Tc 99m Sestamibi Injection
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
Curium Acquires Austrian Radiopharmaceuticals Company IASON
Octreoscan™
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
Inicio
Productos Europa
Seguridad de los medicamentos
Curium Announces Approval of PulmotechTM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration
Curium’s Customers to benefit from Mo-99 Production restart
Curium Is the First North American Manufacturer Offering Exclusively 100% LEU Generators
Sodium Iodide I-123 Capsules
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium to Expand Noblesville Facility’s Workforce
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
Octreoscan™
Curium Prague, Czech Republic
Pulmotech™ MAA
Xenon Xe 133 Gas
Curium y RadioMedix anuncian un acuerdo global en exclusiva para el desarrollo de 64Cu-Dotatate
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
Curium to become major player in the supply on non carrier added Lu-177
Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas
RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application
APhA Annual Meeting & Exposition
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
36th Annual Congress of the European Association of Nuclear Medicine
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
Acerca de Curium
Xenotron™ I
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
Technescan™ HDP
Curium y PIUR IMAGING anuncian una alianza de imágenes de tiroides en Alemania que permitirá soluciones tomográficas de ultrasonidos en 3D
Gallium Citrate Ga 67 Injection
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
ERtracER Solution for Injection
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
30 Years in NETs
Contáctenos
Términos de uso
Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy
Curium Announces Revised Pricing for Technescan MAG3TM (kit for the preparation of technetium Tc 99m mertiatide)
Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio
Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe
Online Ordering (Dublin, Ireland)
Curium anuncia que Pylclari®, un innovador trazador PET 18F-PSMA indicado en pacientes con cáncer de próstata, ya está disponible en España
Declaración de privacidad
IBA Molecular adquiere Mallinckrodt Nuclear Imaging para crear un grupo de primera clase en la industria radiofarmacéutica
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
Política de cookies
Curium adquiere las operaciones comerciales y de fabricación de Cyclopharma en Francia.
Primer Aniversario de Curium Marcado por Logros Históricos
Renaud Dehareng de Curium recibe el galardón top USA CEO 2017
El panel de productores Mo-99 confirma que el suministro es seguro y explica las inversiones realizadas para reforzar el futuro del mismo. El grupo ha tenido un encuentro en la reunión de Medicina Nuclear en Denver
IBA Molecular acquires Mallinckrodt Nuclear Imaging to create world-class radiopharmaceuticals Group
Technescan™ PYP™
Technescan MAG3™
Thallous Chloride Tl 201 Injection
Ética y responsabilidad
Neuraceq
Curium is attending these global congresses in 2024
Qué hacemos
Trabajar en Curium: ¡donde la pasión, la innovación y el talento se unen!
Curium Petten, Nederland
Investigator Initiated Studies
Tekcis®
BNMS – British Nuclear Medicine Society
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]